Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

49.7K
Overview
49.7K
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

3.4K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.4K
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

92
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
92
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.6K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.6K
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

980
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
980
Development of Immunocompetence01:22

Development of Immunocompetence

600
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
600

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oseltamivir drug-disease modelling in infants with influenza virus infection.

British journal of clinical pharmacology·2026
Same author

Molnupiravir Treatment Associated With Clearance of Cache Valley Virus From Cerebrospinal Fluid in an Immunocompromised Child With Meningoencephalitis.

Open forum infectious diseases·2026
Same author

Science for vaccine policy: Lack of transparency, misinformation, and poor decision processes at the December 2025 ACIP meeting.

Vaccine·2026
Same author

The Erosion of a Pillar of Public Health: ACIP's Role and the Future of US Vaccine Policy Post-June 2025.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Advancements and Uncertainties in the Treatment of Congenital CMV Disease.

Reviews in medical virology·2025
Same author

The Role and Safety of Aluminum Adjuvants in Childhood Vaccines.

Pediatrics·2025

Related Experiment Video

Updated: Nov 30, 2025

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.7K

Update From the Advisory Committee on Immunization Practices.

Sean T O Leary1, Yvonne A Maldonado2, David W Kimberlin3

  • 1Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

Journal of the Pediatric Infectious Diseases Society
|November 12, 2020
PubMed
Summary

The Advisory Committee on Immunization Practices (ACIP) is adapting its meeting schedule due to the COVID-19 pandemic, focusing on SARS-CoV-2 vaccine development and recommendations. This update summarizes key discussions from recent ACIP meetings regarding COVID-19 vaccines.

Keywords:
ACIPCDCCOVID-19SARS-CoV-2immunization

More Related Videos

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

9.0K
Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis
06:57

Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis

Published on: May 12, 2023

2.8K

Related Experiment Videos

Last Updated: Nov 30, 2025

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.7K
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

9.0K
Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis
06:57

Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis

Published on: May 12, 2023

2.8K

Area of Science:

  • Immunology and Vaccine Development
  • Public Health Policy
  • Infectious Diseases

Background:

  • The severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) pandemic necessitated rapid vaccine development.
  • The Advisory Committee on Immunization Practices (ACIP) typically meets three times annually but increased frequency due to the pandemic.
  • Several SARS-CoV-2 vaccines were in late-stage clinical trials during this period.

Purpose of the Study:

  • To summarize discussions and recommendations from ACIP meetings held on August 26 and September 22, 2020.
  • To provide updates on the development and potential use of Coronavirus disease 2019 (COVID-19) vaccines.
  • To outline the ACIP's adjusted meeting schedule in response to the ongoing pandemic.

Main Methods:

  • Review of meeting minutes and presentations from ACIP sessions.
  • Focus on discussions pertaining to COVID-19 vaccine candidates.
  • Inclusion of liaisons from pediatric health organizations.

Main Results:

  • ACIP meetings shifted to monthly, single-day sessions to address urgent vaccine development.
  • Discussions centered on the evaluation of SARS-CoV-2 vaccines nearing Emergency Use Authorization.
  • Standard meeting schedules were planned to resume alongside emergency sessions if needed.

Conclusions:

  • ACIP is actively engaged in the evaluation and recommendation process for COVID-19 vaccines.
  • The committee's adaptive meeting schedule ensures timely guidance during the pandemic.
  • Collaboration with pediatric experts is integral to vaccine recommendations for all age groups.